What Opal Therapeutics does

Opal Therapeutics is a women's health biotechnology company developing patient-derived uterine organoid models — endometrial and myometrial — to support drug discovery and preclinical testing for endometriosis, uterine fibroids, and related gynecological conditions. The company's "uterus-in-a-dish" platform combines 3D organoid culture from patient tissue and menstrual effluent with AI-driven analysis of imaging, molecular profiling (RNA-seq, cytokines), and functional readouts to capture patient-specific disease phenotypes. It complements this platform with what it describes as the first large-scale women's health biobank sourced from menstrual blood donations, intended to support longitudinal and diverse-patient studies.

The company monetizes through a sales-led, proposal-based model targeting pharmaceutical companies, biotechnology firms, and academic research groups. Revenue streams include custom research services (project-based fees with fixed and milestone-based components), strategic co-development partnerships with upfront fees and potential licensing/royalties, early discovery screening support, and shipment of cryopreserved organoid specimens with culture protocols. Pricing is not publicly disclosed and is set per proposal. The company operates from a single lab headquarters in San Francisco and is founder-led by CEO Dr. Morgan Stanton, with an advisory board spanning Stanford, Yale, Johnson & Johnson, and Neuralink alumni.

Opal is at an early commercial stage, with disclosed funding concentrated in NSF grants and modest non-dilutive sources. The company has participated in Techstars San Francisco (September 2024), CLS FAST 2025 (September 2025), and NSF I-Corps (May 2025), and is actively publishing white papers and application notes to position its platform within the FDA NAMs and FDA Modernization Act 2.0 regulatory frameworks.

Name

Opal Therapeutics

Legal name

Opal Therapeutics, Inc.

Website

https://opaltherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Opal Therapeutics is a women's health biotech that builds patient-derived uterine organoids and AI-driven analysis tools to enable pharmaceutical, biotechnology, and academic partners to test therapeutics for endometriosis, uterine fibroids, and related gynecological conditions.

Ownership category

akta.pro rank

Product category

Preclinical Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Health Services (8000)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD), Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

Keywords

• Organoid drug discovery
• Women's health biotech
• Preclinical drug testing
• Uterine organoid models
• Endometriosis research

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Research Services: Custom studies using Opal's organoid and assembloid models to evaluate compounds, mechanisms of action, and disease phenotypes for pharmaceutical companies, biotech firms, and academic groups. Revenue is generated through project-based fees invoiced at commencement for fixed fees and after milestone achievement for success fees.
2. Strategic Partnerships: Co-development opportunities with pharmaceutical and biotech companies to build and validate new assays tailored to specific therapeutic areas. Partners may negotiate licenses to use results developed during projects. Revenue may include upfront fees, milestone payments, and potential royalties.
3. Early Discovery Support: Rapid screening services to inform go/no-go decisions and prioritize lead compounds for drug development programs. Enables pharmaceutical companies to evaluate potential therapeutic candidates using human-relevant organoid models before committing to expensive clinical development.
4. Organoid Specimen Sales: Option to ship cryopreserved organoid specimens directly to partner labs, along with detailed culture protocols and media formulation support. Provides additional revenue stream from validated human-derived cell models.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels9 records

Core offering

Opal Therapeutics develops patient-derived 3D uterine organoid models (endometrial and myometrial) built on its 'uterus-in-a-dish' platform, combined with AI-driven analysis for drug screening in endometriosis and uterine fibroids. The company delivers custom research services, strategic co-development partnerships, early discovery screening, and cryopreserved organoid specimens to pharmaceutical, biotechnology, academic, and consumer health clients.

Product overview

Opal Therapeutics is a women's health biotech company offering a unified portfolio of patient-derived uterine organoid products and AI-enabled drug discovery services. The core offering consists of endometrial and myometrial organoids (endometrial organoids replicating the uterus's inner lining and myometrial organoids mimicking the smooth muscle layer) built on the 'uterus-in-a-dish' platform. This platform combines patient-derived 3D organoid models with AI-driven analysis to capture disease phenotypes across imaging, molecular profiling, and functional readouts. Supporting services include a women's health biobank using menstrual blood samples, custom research services, strategic partnerships for assay co-development, and early discovery screening support. The company also produces scientific publications including application notes and white papers on fibroid research and NAM methodologies.

Differentiator

Problem solved

Functional benefit

Products and services

• Endometrial Organoids
• Myometrial Organoids
• Uterus-in-a-Dish Platform
• Women's Health Biobank
• Research Services
• Strategic Partnerships
• Early Discovery Support
• Organoid Specimen Sales

Quantifiable outcome

• Over 90% of drugs that appear safe and effective in animals do not ultimately receive FDA approval, largely due to unforeseen safety or efficacy issues in humans
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• CLS FAST (California Life Sciences FAST)coreGTM or Marketing Partner · 10 September 2025Opal Therapeutics joined the CLS FAST 2025 Accelerator Program in September 2025 to accelerate innovation in women's health through organoid-based drug discovery. California Life Sciences is a prominent industry organization representing California's life sciences sector, providing access to expertise, networking, and resources for emerging biotech companies.
• NSF I-CorpscoreGTM or Marketing Partner · 8 May 2025Opal Therapeutics participated in the NSF I-CORPs program in May 2025, a National Science Foundation initiative designed to accelerate innovation in women's health through advanced organoid models. The program helps researchers explore the commercial potential of scientific discoveries.
• MBC BiolabsminorGTM or Marketing Partner · 24 April 2025MBC Biolabs hosted a Women's Health Innovation Forum in April 2025 where Opal Therapeutics showcased new work in endometriosis. MBC Biolabs is a biotech incubator providing lab space and community for early-stage life sciences companies.
• TechstarscoreGTM or Marketing Partner · 9 September 2024Opal Therapeutics was selected for Techstars inaugural San Francisco accelerator class in September 2024. The program provides mentorship, resources, and networking opportunities to help accelerate the company's growth and connect with potential investors and partners in the biotech ecosystem. CEO Morgan Stanton presented at Techstars Demo Day in December 2024 as the first pitch.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Myovant Sciences (Pfizer): Myovant (acquired by Pfizer) markets Myfembree for uterine fibroids and endometriosis, representing a downstream pharma customer for Opal's organoid screening services and a comparable women's health commercial footprint.
• Bayer (Women's Health): Bayer has an active women's health franchise including fibroid therapies (e.g., Essure-era devices, current pipeline) and is a likely organoid-services customer. Comparable as a broad incumbent with overlapping indication focus.
• AbbVie: AbbVie markets Orilissa/Oriahnn for endometriosis and is a leading women's health therapeutics incumbent. Potential large-pharma customer for organoid-based preclinical services addressing the same indications Opal models.

Emerging players

• DotLab: DotLab develops blood-based molecular diagnostics and biomarker tests for endometriosis, sharing Opal's endometriosis focus but approaching the problem through diagnostics rather than organoid drug discovery.
• Hera Biotech: Hera Biotech is developing non-invasive molecular diagnostics for endometriosis, addressing the same patient population Opal serves via drug discovery but through a diagnostic rather than therapeutic screening platform.

Direct peers

• Mimetas: Mimetas builds organ-on-chip and 3D tissue models (OrganoPlate) used by pharma for compound screening and toxicity testing. Overlaps with Opal's drug screening and disease modeling services for pharma and biotech customers.
• Newcells Biotech: Newcells Biotech offers organoid and iPSC-derived disease models for preclinical drug testing in ophthalmology, kidney, and CNS. Comparable CRO-style organoid services serving pharma discovery pipelines.
• Organovo: Organovo develops 3D bioprinted human tissue models for drug discovery and disease research. Comparable in offering human-derived tissue platforms to pharma partners, though historically focused on liver and oncology indications.
• InSphero: InSphero provides 3D in vitro microtissue and organoid models for drug discovery and safety testing. Directly comparable service-based business model serving pharma, biotech, and academic researchers with human-relevant preclinical assays.
• Emulate: Emulate's organ-on-chip platform (Liver-Chip, etc.) is the closest commercial analog to Opal's organoid-based preclinical testing approach. Both target pharma R&D with human-relevant NAMs for IND-enabling data, but Emulate operates at broader organ scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/opal-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opal Therapeutics